文献速递肿瘤 PET/CT

用放射性标记重组人PD-1可视化非小细胞肺癌中PD-L1表达的动态变化

Visualizing dynamic changes in PD-L1 expression in non-small cell lung carcinoma with radiolabeled recombinant human PD-1.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-01-28

本研究分析了102例肺癌患者中PD-L1表达的预后意义,并制备64Cu-NOTA-rhPD1 PET示踪剂,在PD-L1高表达HCC827与低表达A549荷瘤小鼠中验证靶向特异性及对PD-L1阻断治疗相关PD-L1表达变化的监测能力,结果示踪剂可灵敏监测治疗相关PD-L1变化且似优于[18F]FDG。

要点

  • PD-L1被证明是非小细胞肺癌的良好预后标志物,其表达与组织学相关。
  • 64Cu-NOTA-rhPD1在HCC827肿瘤3小时摄取为9.0 ± 0.5%ID/g,A549为3.2 ± 0.4%ID/g。
  • PET显示64Cu-NOTA-rhPD1可灵敏监测治疗相关PD-L1表达变化,似优于[18F]FDG。

核心结论

  • PD-L1被确定为手术切除非小细胞肺癌的良好预后标志物。
  • 研究开发出对PD-L1具有高靶向特异性的PET示踪剂64Cu-NOTA-rhPD1。

研究设计与样本

  • 分析102例肺癌患者队列,研究PD-L1表达水平的预后意义。
  • 表达、纯化重组人PD-1胞外域蛋白(rhPD1)并用64Cu标记以评估肿瘤PD-L1状态。
  • 使用皮下荷PD-L1高表达肿瘤HCC827与PD-L1低表达肿瘤A549的小鼠,确定示踪剂靶向特异性并考察PD-L1阻断治疗反应效果。

主要发现

  • PD-L1被证明是非小细胞肺癌的良好预后标志物,其表达与NSCLC组织学相关。
  • 注射后3小时,64Cu-NOTA-rhPD1在HCC827肿瘤的摄取为9.0 ± 0.5%ID/g,在A549肿瘤为3.2 ± 0.4%ID/g。
  • 注射后3小时,64Cu标记变性rhPD1在HCC827肿瘤的摄取较低,为3.1 ± 0.3%ID/g(p < 0.001),证明64Cu-NOTA-rhPD1的靶向特异性。
  • PET显示64Cu-NOTA-rhPD1可灵敏监测治疗相关PD-L1表达变化,且似乎优于[18F]FDG。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tumor heterogeneity limits the predictive value of PD-L1 expression and influences the outcomes of the immunohistochemical assay for therapy-induced changes in PD-L1 levels. This study aimed to determine the predictive value of PD-L1 for non-small cell lung carcinoma (NSCLC), thereby developing imaging agents to non-invasively image and examine the effect of the therapeutic response to PD-L1 blockade therapy. METHODS: A cohort of 102 patients with lung cancer was analyzed, and the prognostic significance of PD-L1 expression level was investigated. Recombinant human PD-1 ECD protein (rhPD1) was expressed, purified, and labeled with 64Cu for the evaluation of PD-L1 status in tumors. Mice subcutaneously bearing PD-L1 high-expressing tumor HCC827 and PD-L1 low-expressing tumor A549 were used to determine tracer-target specificity and examine the effect of therapeutic response to PD-L1 blockade therapy. RESULTS: PD-L1 was proved to be a good prognosis marker for NSCLC, and its expression was correlated with the histology of NSCLC. PET imaging revealed high tumor accumulation of 64Cu-NOTA-rhPD1 in HCC827 tumors (9.0 ± 0.5%ID/g), whereas it was 3.2 ± 0.4%ID/g in A549 tumors at 3 h post-injection. The lower tumor uptake (3.1 ± 0.3%ID/g) of 64Cu-labeled denatured rhPD1 in HCC827 tumors at 3 h post-injection (p < 0.001) demonstrated the target specificity of 64Cu-NOTA-rhPD1. Furthermore, PET showed that 64Cu-NOTA-rhPD1 sensitively monitored treatment-related changes in PD-L1 expression, and seemed to be superior to [18F]FDG. CONCLUSION: We identified PD-L1 as a good prognosis marker for surgically resected NSCLC and developed the PET tracer 64Cu-NOTA-rhPD1 with high target specificity for PD-L1.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Luo H, Yang C, Kuang D, et al. Visualizing dynamic changes in PD-L1 expression in non-small cell lung carcinoma with radiolabeled recombinant human PD-1. Eur J Nucl Med Mol Imaging. 2022. PMID: 35089375. doi:10.1007/s00259-022-05680-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。